Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase. For more information, please visit www.thryvtrx.com.
Industry
Biotechnology Research, Scientific Research and Development Services, Services
HQ Location
999, boulevard De Maisonneuve Ouest
Suite 1250
Montréal, Québec H3A 3L4, CA
Keywords
selective inhibitorsprecision medicine fundmedicine fundpharmaceutical commercializationnote financingtreatment resistant cancerspipeline leads